Iridex Corp (NASDAQ: IRIX) reported insider buying on February 17, 2026, when Chief Financial Officer Romeo R. Dizon purchased a total of 2,200 shares of common stock for $2,942. The acquisitions were made in two trades at prices between $1.31 and $1.37 per share.
Specifically, Dizon bought 1,000 shares at $1.37 and 1,200 shares at $1.31. After these transactions, his direct holdings in Iridex amount to 119,890 shares. At the time of the purchases the company’s shares were trading around $1.33. Independent analysis referenced by the company framework suggests the stock appears fairly valued on its present fundamentals.
Iridex, a medical technology firm, has a market capitalization of $22.7 million. The stock has posted a 22.1% price gain over the past six months. This market momentum has occurred despite the company reporting negative earnings of -$0.30 per share over the trailing twelve months. Investors are approaching the company’s scheduled earnings release on March 5, 2026, which is 16 days from the February 17 transaction date.
Alongside the insider activity, Iridex released preliminary unaudited fourth-quarter financial results showing revenue between $14.6 million and $14.8 million, representing a 15-17% increase versus the same quarter a year earlier. The company also reported it generated positive cash flow during the fourth quarter and expects to report positive adjusted EBITDA for the full year 2025.
Operationally, Iridex disclosed plans to move its corporate headquarters from Mountain View to San Jose, California. The relocation is projected to deliver roughly $0.4 million in cost savings in fiscal year 2026 and approximately $0.6 million in annual savings thereafter.
On the clinical front, a newly published independent study in the journal Ophthalmology and Therapy evaluated Iridex’s MicroPulse transscleral laser technology. Conducted at the University Eye Clinic Maastricht, the study found significant reductions in intraocular pressure among patients who underwent retreatment using the MicroPulse approach, underscoring efficacy signals for that product application.
These combined developments - modest insider purchases, improving revenue and cash flow metrics, an anticipated positive adjusted EBITDA for 2025, cost savings from the headquarters move, and supportive clinical data - outline the company’s current trajectory as it approaches its next earnings report. The size of the insider transactions was small relative to total shares outstanding and market capitalization, while the company continues to report trailing negative earnings per share.